FilingSEC EDGAR8-K
Pyxis Oncology Reports Q3 Results and Outlines Phase 3 Development Plan for MICVO
· SEC accepted
StagePhase 1/Phase 3 Preparation
Filing content
The company reported its third quarter 2026 financial results and provided updates on MICVO Phase 1 data and the planned initiation of a global Phase 3 trial in mid-2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…